Amerise Biosciences Ltd

Amerise Biosciences Ltd

Amerise Biosciences Ltd has updated its website address and requested BSE to update their records with the new website details.

Amerise Biosciences Ltd

Amerise Biosciences Ltd submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026, confirming the dematerialization of securities.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has announced the voting results of its 41st Annual General Meeting (AGM) held on September 24, 2026. The company has reported that all resolutions passed with 100% votes in favor. The resolutions included the adoption of audited financial statements for the Financial Year ended March 31, 2026, and the appointment of Mr. Albert Hines as a Whole-time Director and Chief Financial Officer.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has announced the outcome of its 41st Annual General Meeting (AGM) held on September 24, 2026, where two ordinary resolutions were passed, including the adoption of audited financial statements for FY 2025-26 and the appointment of Mr. Albert Hines as Whole-time Director and Chief Financial Officer.

Amerise Biosciences Ltd

Amerise Biosciences Ltd, a company in the Others category, has submitted its Annual Report for the financial year 2025-26, along with the Notice of 41st Annual General Meeting to be held on September 24, 2026. The report includes the audited financial statements, reports of the Board of Directors and Auditors, and other relevant information.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has announced a book closure from September 17, 2026, to September 24, 2026, for its Annual General Meeting on September 24, 2026.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has submitted a notice of its 41st Annual General Meeting (AGM) to be held on September 24, 2026, where it will consider the appointment of Albert Hines as Whole Time Director and CFO, and other business.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Snehjeev Ventures Pvt Ltd and PACs regarding a substantial acquisition of shares.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026, with a net loss of Rs. 8.14 crores and earnings per share of Rs. 0.01.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026, with a net loss of Rs. 8.14 lakhs. The company's revenue from operations was Rs. 7.92 lakhs, and its expenses totaled Rs. 8.14 lakhs. The net loss after tax was Rs. 8.14 lakhs, and the earnings per share was Rs. 0.01.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company's revenue from operations was Rs. 7.92 lakhs, with a profit before tax of Rs. (8.14) lakhs. The net loss after tax was Rs. (8.14) lakhs. The company's earnings per share (EPS) was (0.01) for the quarter.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Snehjeev Ventures Pvt Ltd & PACs.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Snehjeev Ventures Pvt Ltd and PACs regarding a potential substantial acquisition.

Amerise Biosciences Ltd

Amerise Biosciences Ltd has scheduled a Board meeting on 03/08/2026 to consider and approve the unaudited financial results for the first quarter ended 30/06/2026.